Form 4: Organon CIO Rachel Stahler Reports Equity Transactions

Chief Information Officer Rachel Stahler exercised restricted stock units and withheld shares for tax obligations.

Summary

• Rachel A. Stahler, Chief Information Officer of Organon & Co., reported the vesting and settlement of restricted stock units (RSUs).
• A total of 18,867 shares were acquired through the vesting of RSUs on March 31, 2026.
• The company withheld 6,463 shares to satisfy tax withholding obligations at a price of $5.70 per share.
• A new grant of 183,639 RSUs was awarded to the reporting person, vesting in three equal annual installments starting March 31, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• The reporting person maintains a significant direct ownership stake of 116,105.292 shares following the transactions.
• The issuance of 183,639 new RSUs aligns executive compensation with long-term shareholder value through multi-year vesting.

Negatives

• The transaction involved the withholding of 6,463 shares to cover tax liabilities, which is a standard but dilutive event for the individual's holdings.

Risks

• Future share price volatility could impact the value of the newly granted 183,639 RSUs.
• The vesting of equity is subject to continued employment, creating potential retention risk if the executive departs.

Future Outlook

The reporting person has been granted 183,639 RSUs that will vest in three equal annual installments on March 31, 2027, 2028, and 2029, contingent upon continued service.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive equity compensation, common in the pharmaceutical and biotech sectors to ensure alignment between leadership and long-term corporate performance.

Comparison to Industry Standards

• The use of three-year graded vesting for RSUs is consistent with standard executive compensation practices at large-cap pharmaceutical companies like Merck or Pfizer.
• Tax withholding at the time of vesting is a standard administrative procedure for equity-based compensation.

Stakeholder Impact

• Shareholders should note the dilution impact of new RSU grants, though these are standard components of executive retention packages.

Next Steps

• Vesting of the first installment of the new RSU grant on March 31, 2027.

Key Dates

Keywords

Organon, OGN, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Executive Compensation